Overcoming Temozolomide Resistance in Glioblastoma via Enhanced NAD(+) Bioavailability and Inhibition of Poly-ADP-Ribose Glycohydrolase

SIMPLE SUMMARY: Glioblastoma is the most prevalent and lethal brain tumor type, often treated with the DNA alkylating agent temozolomide (TMZ). The cytotoxic DNA lesion O(6)-methylguanine only accounts for about 9% of the DNA lesions induced by TMZ. The other DNA lesions (>80%) are quickly repair...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Jianfeng, Koczor, Christopher A., Saville, Kate M., Hayat, Faisal, Beiser, Alison, McClellan, Steven, Migaud, Marie E., Sobol, Robert W.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9331395/
https://www.ncbi.nlm.nih.gov/pubmed/35892832
http://dx.doi.org/10.3390/cancers14153572

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9331395/
https://www.ncbi.nlm.nih.gov/pubmed/35892832
http://dx.doi.org/10.3390/cancers14153572

Ejemplares similares